# Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

> **NCT06285240** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 28 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MK-1167
- **DRUG:** Donepezil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06285240
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-28
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06285240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06285240, "Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06285240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*